Sanofi Pasteur, the vaccines division of Sanofi, has
launched its paediatric pentavalent vaccine, 'Shan5', developed and
manufactured by its affiliate Shantha in India.
The vaccine is a fully-liquid five-in-one, convenient, safe and high-quality
vaccine that provides efficient protection for children from 6 weeks against
five diseases: diphtheria, tetanus,pertussis, Hib and hepatitis B.
The launch of 'Shan5' vaccine acquired prequalification status from the World
Health Organization (WHO) last April. Shan5's prequalification gives many more children in India
access to the latest high- quality, fully-liquid, 5-in-1 vaccine.
Further, the prequalification helps Shan5 secure the supply
of pentavalent combination vaccines in over 50 low-income countries. It adds to the current list of four vaccines that Shantha
manufactures that includes Shanchol-the innovative cholera vaccine.
"A significant number of babies born every year in India do
not have access to modern vaccination programmes. The launch of Shan5 in India
means that 27 million babies born annually in India will have access to
vaccination, to protect them from 5 potentially deadly diseases. By launching
Shan5, Shantha will be contributing to filling this immunization gap for the
benefit of babies and their parents", said Dr.Harish Iyer, CEO-Shantha.
Shan5 vaccine has been developed and is produced by Shantha
in Hyderabad, India.
Shantha is a biotechnology pioneer from the
emerging countries, founded by Dr. K I Varaprasad Reddy in 1993 in Hyderabad,
Shantha and Sanofi Pasteur are also developing a new
pediatric combination vaccine based on Shan5 that will incorporate Sanofi
Pasteur's Inactivated Polio Vaccine in order to secure polio eradication.